Attending Physician in the Mount Sinai Cardiovascular Institute
Dr. Sameer Bansilal is a clinician and investigator with a broad range of expertise in cardiovascular medicine and outcomes research on a global scale. Dr. Bansilal is currently an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai and an Attending Physician in the Mount Sinai Cardiovascular Institute. Over the last decade, he has trained as a clinical trialist and a global health outcomes researcher at Mount Sinai, NYU, Brigham and Women’s Hospital and the Harvard School of Public Health. During this time, he has had the opportunity to work on various NIH and pharmaceutical sponsored clinical trials and global health projects. He has served as a co-investigator for the FREEDOM trial (NIH-UO1; 1900 patients), PEGASUS-TIMI 54 (21,000 patients worldwide) and DECLARE-TIMI 58 (17,150 patients worldwide). He has served as the medical lead for the Grenada Heart Project, a cardiovascular risk factor survey of 2,827 subjects in the Caribbean Islands of Grenada and as a co-investigator for the High-risk plaque project (6000 patients) with multimodal imaging for prediction of cardiovascular events. Finally, he is currently serving as the medical lead on the Polypill evaluation studies in the United States to look at whether providing a fixed-dose combination improves adherence and is cost-effective. Dr. Bansilal’s clinical and research interests center on therapies for coronary disease, diabetes and asymptomatic patients with various heart disorders in global populations. His special interests include advanced trial design and trial methodology.
2 blogs from the author
Posted on 29.07.2014
Superbugs: “The physician community needs to get its act together”
The WHO has been raising the ‘threat level’ on this issue progressively each year for the last decade, with individual disease reports highlighting the emerging threat of antimicrobial resistance (AMR). This year’s report however highlights this pandemic like never before, demonstrating it’s global nature and its profound impact on health and economics. I’m a cardiologist and the report speaks to me – actually it screams out loud: “We need to get our act together”.
iWatch: Not so fast Apple
The lure of wearable technology and its application to health is tremendous- so tremendous that even the richest company on the planet-Apple, can’t resist it apparently. And so goes the recent insider news that has captured the attention of people worldwide “Apple is developing software and sensors that can predict heart attacks”. Not so fast Apple, not so fast….